ClinicalTrials.gg
CompletedNCT01509638IMPROVE-IRUpdated Mar 6, 2014Results posted

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501

A Phase 4 interventional study of Group 1 Standard of Care and Group 2 EXPAREL in Retraction of Colostomy, sponsored by Pacira Pharmaceuticals, Inc. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Read the detailed description

This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL (bupivacaine liposome injectable suspension) compared with postsurgical administration of standardized intravenous (IV) morphine sulfate or Sponsor-approved equivalent for postsurgical analgesia in adult patients undergoing ileostomy reversal with general anesthesia.

02

Conditions studied

  • Retraction of Colostomy

Keywords

  • Ileostomy reversal
03

In context

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years of age or older.
  • Patients scheduled to undergo ileostomy reversal.
  • Ability to provide , adhere to study visit schedule, and complete all assessments.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.
  • Patients who abuse alcohol or other drug substance.
  • Patients with severe hepatic impairment.
  • Patients currently pregnant or who may become pregnant during the course of the study or who are unwilling to use acceptable means of for at least one month before and one month after dosing.
  • Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.
  • Patients who have participated in an EXPAREL study within the last 30 days.
  • Patients who have received an drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.

In addition, the patient will be ineligible if he/she meets the following criteria during surgery:

  • Patients who have any concurrent surgical procedure.
  • Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or any other analgesic, local anesthetics, or anti-inflammatory agents.
  • Patients who receive Entereg(R).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Active comparator
    Group 1 Standard of Care

    IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump

    Drug: Group 1 Standard of Care

  • Active comparator
    Group 2 EXPAREL

    bupivacaine liposome injectable suspension.

    Drug: Group 2 EXPAREL

Interventions

  • DrugGroup 1 Standard of Care

    Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.

  • Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.

    Also known as: bupivacaine liposome injectable suspension

06

What researchers measure

Primary outcomes

  1. Total Opioid Burden

    Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner

  2. Health Economic Benefits

    Total cost of hospitalization until the time the discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  3. Health Economic Benefit

    Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

Secondary outcomes

  1. Incidence of Opioid-related Adverse Events

    Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  2. Patient Satisfaction With Postsurgical Analgesia

    Responses to one question pertaining to patient satisfaction with postsurgical analgesia

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  3. Patient Discharged From Hospital for at Least 3 Days

    Yes, if patient discharged from hospital for at least 3 days; no, if patient not discharged from hospital for at least 3 day; not reported, if applicable.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  4. Patient Made Unplanned Visit(s) With Any Healthcare Providers

    Yes, if patient made unplanned visit(s); No, if patient did not make unplanned visits; not reported, if applicable

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  5. Contact or Attempted to Contact Surgeon/Doctor to Discuss Recovery After Surgery

    Yes, if contacted or attempted to contact; No, if did not contact and did not attempt to contact; not reported, if applicable.

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  6. Experienced Health Problems or Changes in Health Since Hospital Discharge

    Yes, if experienced health problems or changes in health; No, if did not experience health problems or changes in health; not reported, if applicable

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

  7. Time to First Opioid Administration

    Time in hours to first opioid administration

    Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.

07

Results

Posted Mar 6, 2014

Participant flow

Participant flow — Overall Study
MilestoneGroup 1 Standard of CareGroup 2 EXPAREL
Started2326
Completed2024
Not completed32

Outcome measures

PrimaryTotal Opioid Burden

Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner
Reported as:
Mean · mg morphine equivalent
Total Opioid Burden
mg morphine equivalentGroup 1 Standard of CareGroup 2 EXPAREL
Total Opioid Burden67.7 ± 46.6438.41 ± 45.85
PrimaryHealth Economic Benefits

Total cost of hospitalization until the time the discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Mean · dollars
Health Economic Benefits
dollarsGroup 1 Standard of CareGroup 2 EXPAREL
Health Economic Benefits7284.63 ± 3577.427010.16 ± 2709.56
PrimaryHealth Economic Benefit

Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Median · days
Health Economic Benefit
daysGroup 1 Standard of CareGroup 2 EXPAREL
Health Economic Benefit4 (2 to 7)3 (1 to 15)
SecondaryIncidence of Opioid-related Adverse Events

Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Mean · number of events
Incidence of Opioid-related Adverse Events
number of eventsGroup 1 Standard of CareGroup 2 EXPAREL
Incidence of Opioid-related Adverse Events0.1 ± 0.220.1 ± 0.29
SecondaryPatient Satisfaction With Postsurgical Analgesia

Responses to one question pertaining to patient satisfaction with postsurgical analgesia

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants
Patient Satisfaction With Postsurgical Analgesia
participantsGroup 1 Standard of CareGroup 2 EXPAREL
Extremely Satisfied811
Satisified79
Neither Satisfied nor Dissatisfied12
Dissatisfied01
Not Reported40
SecondaryPatient Discharged From Hospital for at Least 3 Days

Yes, if patient discharged from hospital for at least 3 days; no, if patient not discharged from hospital for at least 3 day; not reported, if applicable.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants
Patient Discharged From Hospital for at Least 3 Days
participantsGroup 1 Standard of CareGroup 2 EXPAREL
Patient Discharged From Hospital for at Least 3 Days1622
SecondaryPatient Made Unplanned Visit(s) With Any Healthcare Providers

Yes, if patient made unplanned visit(s); No, if patient did not make unplanned visits; not reported, if applicable

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants who answered yes
Patient Made Unplanned Visit(s) With Any Healthcare Providers
participants who answered yesGroup 1 Standard of CareGroup 2 EXPAREL
Patient Made Unplanned Visit(s) With Any Healthcare Providers24
SecondaryContact or Attempted to Contact Surgeon/Doctor to Discuss Recovery After Surgery

Yes, if contacted or attempted to contact; No, if did not contact and did not attempt to contact; not reported, if applicable.

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants who answered yes
Contact or Attempted to Contact Surgeon/Doctor to Discuss Recovery After Surgery
participants who answered yesGroup 1 Standard of CareGroup 2 EXPAREL
Contact or Attempted to Contact Surgeon/Doctor to Discuss Recovery After Surgery52
SecondaryExperienced Health Problems or Changes in Health Since Hospital Discharge

Yes, if experienced health problems or changes in health; No, if did not experience health problems or changes in health; not reported, if applicable

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Number · participants who answered yes
Experienced Health Problems or Changes in Health Since Hospital Discharge
participants who answered yesGroup 1 Standard of CareGroup 2 EXPAREL
Experienced Health Problems or Changes in Health Since Hospital Discharge45
SecondaryTime to First Opioid Administration

Time in hours to first opioid administration

Time frame:
Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Reported as:
Median · hours
Time to First Opioid Administration
hoursGroup 1 Standard of CareGroup 2 EXPAREL
Time to First Opioid Administration0.7 (0.3 to 3.6)1.1 (0.3 to 71)

Adverse events

Collected over 30 days post surgery. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 Standard of Care—0/22 (0%)18/22 (81.8%)
Group 2 EXPAREL—3/25 (12%)15/25 (60%)
Most frequent serious events
Most frequent serious events
EventGroup 1 Standard of CareGroup 2 EXPAREL
Gastrointestinal hemorrhageGastrointestinal disorders0/221/25
Anastomotic leakInjury, poisoning and procedural complications0/221/25
PeritonitisGastrointestinal disorders0/221/25
Small intestinal obstructionGastrointestinal disorders0/221/25
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/221/25
Systemic inflammatory response syndromeImmune system disorders0/221/25
Renal failure acuteRenal and urinary disorders0/221/25
Anastomatic complicationsInjury, poisoning and procedural complications0/221/25
Most frequent other events
Showing 10 of 25
Most frequent other events
EventGroup 1 Standard of CareGroup 2 EXPAREL
DiarrheaGastrointestinal disorders3/223/25
Wound infectionInfections and infestations2/221/25
HypokalemiaMetabolism and nutrition disorders0/222/25
Abdominal painGastrointestinal disorders1/220/25
DyspepsiaGastrointestinal disorders1/220/25
Pyoderma gangrinosumGastrointestinal disorders1/220/25
VomitingGastrointestinal disorders1/220/25
Edema peripheralGeneral disorders1/220/25
Postprocedural hemorrhageInjury, poisoning and procedural complications1/220/25
Procedural site reactionInjury, poisoning and procedural complications1/220/25

Baseline characteristics

23 patients in Group 1 and 25 patients in Group 2 were enrolled. 22 patients from Group 1 and 23 patients from Group 2 were in the Safety Analysis Set (patients who underwent planned surgery).

Age, Continuous
Age, Continuous(years)Group 1 Standard of CareGroup 2 EXPARELTotal
Mean47.1 ± 17.8748.2 ± 14.5347.7 ± 16.01
Age, Categorical
Age, Categorical(Participants)Group 1 Standard of CareGroup 2 EXPARELTotal
<=18 years000
Between 18 and 65 years182442
>=65 years415
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 Standard of CareGroup 2 EXPARELTotal
Female81119
Male141428
Region of Enrollment
Region of Enrollment(participants)Group 1 Standard of CareGroup 2 EXPARELTotal
United States222547
08

Study locations

2 sites
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Cleveland Clinic Ohio
    Beachwood, Ohio 44122, United States
09

References and documents

Publications

  • Cohen SM, Vogel JD, Marcet JE, Candiotti KA. Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis. J Pain Res. 2014 Jun 24;7:359-66. doi: 10.2147/JPR.S63764. eCollection 2014. PubMed 25018650 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Jan 13, 2012
Start
Mar 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Mar 6, 2014
Last update
Mar 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01509638
Collaborators
Registrat-Mapi
Responsible party
Sponsor
First posted
Jan 13, 2012
Start date
Mar 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Mar 6, 2014
Last update
Mar 6, 2014

Study contacts

Marylise Boutros, M.D.
principal investigator · Cleveland Clinic Florida

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion